BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17502947)

  • 1. Angiogenesis and ER/PR status in primary breast cancer patients: an analysis of 158 needle core biopsies.
    Vameşu S
    Rom J Morphol Embryol; 2007; 48(1):25-31. PubMed ID: 17502947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis and progesterone receptor status in primary breast cancer patients: an analysis of 158 needle core biopsies.
    Vameşu S
    Rom J Morphol Embryol; 2007; 48(3):267-74. PubMed ID: 17914494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis and tumor histologic type in primary breast cancer patients: an analysis of 155 needle core biopsies.
    Vameşu S
    Rom J Morphol Embryol; 2008; 49(2):181-8. PubMed ID: 18516324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis and tumor grading in primary breast cancer patients: an analysis of 158 needle core biopsies.
    Vameşu S
    Rom J Morphol Embryol; 2006; 47(3):251-7. PubMed ID: 17308684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies.
    Vameşu S
    Rom J Morphol Embryol; 2007; 48(2):121-9. PubMed ID: 17641798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis and co-expressed of ER and c-erbB-2 (HER2/neu) protein in primary breast cancer patients: an analysis of 158 needle core biopsies.
    Vameşu S
    Rom J Morphol Embryol; 2008; 49(4):469-78. PubMed ID: 19050794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer.
    Jang KS; Han HX; Paik SS; Brown PH; Kong G
    Cancer Lett; 2006 Dec; 244(2):203-10. PubMed ID: 16469432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital.
    Lertsanguansinchai P; Chottetanaprasith T; Chatamra K; Sampatanukul P; Wannakrairot P; Rojpornpradit P; Shotelersuk K; Lertbutsayanukul C; Boonjunwetwat D; Vajragupta L
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S193-202. PubMed ID: 12188412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
    Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of estrogen and progesterone receptors in human ductal invasive breast carcinoma not otherwise specified: is there any difference between premenopausal and postmenopausal women?
    Petricević J; Petković M; Jonjić N
    Acta Clin Croat; 2011 Jun; 50(2):169-75. PubMed ID: 22263379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear areas in breast cancer: relationship with estrogen and progesterone receptor expression.
    Maiorana A; Cavallari V; Bagni A; Ussia F; Maiorana MC; Fano RA
    Anal Cell Pathol; 1996 Aug; 11(3):199-209. PubMed ID: 8888955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer.
    Park SY; Kim KS; Lee TG; Park SS; Kim SM; Han W; Noh DY; Kim SW
    Am J Surg; 2009 Feb; 197(2):266-9. PubMed ID: 18614146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
    Keshgegian AA; Cnaan A
    Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
    Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
    Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.